Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Shiv K Sarin, Manoj Kumar, Mohammed Eslam, Jacob George, Mamun Al Mahtab, Sheikh M Fazle Akbar, Jidong Jia, Qiuju Tian, Rakesh Aggarwal, David H Muljono, Masao Omata, Yoshihiko Ooka, Kwang-Hyub Han, Hye Won Lee, Wasim Jafri, Amna S Butt, Chern H Chong, Seng G Lim, Raoh-Fang Pwu, Ding-Shinn Chen, Shiv K Sarin, Manoj Kumar, Mohammed Eslam, Jacob George, Mamun Al Mahtab, Sheikh M Fazle Akbar, Jidong Jia, Qiuju Tian, Rakesh Aggarwal, David H Muljono, Masao Omata, Yoshihiko Ooka, Kwang-Hyub Han, Hye Won Lee, Wasim Jafri, Amna S Butt, Chern H Chong, Seng G Lim, Raoh-Fang Pwu, Ding-Shinn Chen

Abstract

The Asia-Pacific region is home to more than half of the global population and accounted for 62·6% of global deaths due to liver diseases in 2015. 54·3% of global deaths due to cirrhosis, 72·7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute viral hepatitis occurred in this region in 2015. Chronic hepatitis B virus (HBV) infection caused more than half of the deaths due to cirrhosis in the region, followed by alcohol consumption (20·8%), non-alcoholic fatty liver disease (NAFLD; 12·1%), and chronic infection with hepatitis C virus (HCV; 15·7%). In 2015, HBV accounted for about half the cases of hepatocellular carcinoma in the region. Preventive strategies for viral hepatitis-related liver disease include increasing access to clean drinking water and sanitation. HBV vaccination programmes for neonates have been implemented by all countries, although birth-dose coverage is extremely suboptimal in some. Availability of screening tests for blood and tissue, donor recall policies, and harm reduction strategies are in their initial stages in most countries. Many governments have put HBV and HCV drugs on their essential medicines lists and the availability of generic versions of these drugs has reduced costs. Efforts to eliminate viral hepatitis as a public health threat, together with the rapid increase in per-capita alcohol consumption in countries and the epidemic of obesity, are expected to change the spectrum of liver diseases in the Asia-Pacific region in the near future. The increasing burden of alcohol-related liver diseases can be contained through government policies to limit consumption and promote less harmful patterns of alcohol use, which are in place in some countries but need to be enforced more strictly. Steps are needed to control obesity and NAFLD, including policies to promote healthy lifestyles and regulate the food industry. Inadequate infrastructure and insufficient health-care personnel trained in liver diseases are issues that also need to be addressed in the Asia-Pacific region. The policy response of most governments to liver diseases has thus far been inadequate and poorly funded. There must be a renewed focus on prevention, early detection, timely referral, and research into the best means to introduce and improve health interventions to reduce the burden of liver diseases in the Asia-Pacific region.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Liver-related deaths as proportion of overall deaths in the Asia-Pacific region
Figure 2
Figure 2
Causes of liver-related deaths by country in the Asia-Pacific region
Figure 3
Figure 3
Causes of cirrhosis-related deaths by country in the Asia-Pacific region
Figure 4
Figure 4
Causes of liver cancer-related deaths by country in the Asia-Pacific region
Figure 5
Figure 5
Causes of acute hepatitis-related deaths by country in the Asia-Pacific region
Figure 6
Figure 6
Distribution of (A) all liver-related, (B) hepatitis-related, (C) cirrhosis-related, and (D) liver cancer-related deaths per HDI in the Asia-Pacific region HDI=Human Development Index.
Figure 7
Figure 7
Distribution of (A) HBV-related and (B) HAV-related and HEV-related deaths from acute hepatitis per HDI in the Asia-Pacific region HDI=Human Development Index.
Figure 8
Figure 8
Distribution of deaths from cirrhosis due to (A) HBV infection, (B) HCV infection, (C) alcohol consumption, and (D) other causes per HDI in the Asia-Pacific region HDI=Human Development Index.
Figure 9
Figure 9
Distribution of deaths from liver cancer due to (A) HBV infection, (B) HCV infection, (C) alcohol consumption, and (D) other causes per HDI in the Asia-Pacific region HDI=Human Development Index.

References

    1. WHO Global Health Estimates 2015: deaths by cause, age, sex, by country and by region, 2000–2015. 2016.
    1. World Bank Country profiles. 2017.
    1. Ministry of Health Singapore Communicable diseases surveillance in Singapore 2016. 2017.
    1. Cooke GS, Andrieux-Meyer I, Applegate TL. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135–184.
    1. Shan S, Cui F, Jia J. How to control highly endemic hepatitis B in Asia. Liver Int. 2018;38(suppl 1):122–125.
    1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555.
    1. Polaris Observatory Collaborators Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.
    1. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(suppl 1):7–10.
    1. Cui F, Shen L, Li L. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23:765–772.
    1. Zhang S, Ma Q, Liang S. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat. 2016;23:202–210.
    1. Qin Q, Smith MK, Wang L. Hepatitis C virus infection in China: an emerging public health issue. J Viral Hepat. 2015;22:238–244.
    1. Sun M, Xu N, Li C. The public health emergency management system in China: trends from 2002 to 2012. BMC Public Health. 2018;18:474–482.
    1. Wu E, Yang M, Rao H. Temporal changes in the modes of hepatitis C virus transmission in the USA and northern China. Dig Dis Sci. 2017;62:2141–2149.
    1. Piao H-X, Yang A-T, Sun Y-M. Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China. PLoS One. 2014;9
    1. Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of transmission routes of hepatitis C virus based on virus genotyping in 341 cases with different suspected initial infection time points in Hunan Province, China. Med Sci Monit. 2018;24:5232–5241.
    1. GBD 2015 Mortality and Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544.
    1. Islami F, Dikshit R, Mallath MK, Jemal A. Primary liver cancer deaths and related years of life lost attributable to hepatitis B and C viruses in India. Cancer Epidemiol. 2016;40:79–86.
    1. Puri P. Tackling the hepatitis B disease burden in India. J Clin Exp Hepatol. 2014;4:312–319.
    1. Thyagarajan SP, Jayaram S, Mohanavalli B. Prevalence of HBV in general population of India. In: Sarin SK, Singal AK, editors. Hepatitis B in India: prevention and management. CBS Publishers and Distributors; New Delhi: 2005. pp. 5–16.
    1. Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Sytematic review and meta-analysis of prevalence of hepatitis B in India. Indian Pediatr. 2007;44:663–674.
    1. Batham A, Gupta MA, Rastogi P, Garg S, Sreenivas V, Puliyel JM. Calculating prevalence of hepatitis B in India: using population weights to look for publication bias in conventional meta-analysis. Indian J Pediatr. 2009;76:1247–1257.
    1. Gupta S, Gupta R, Joshi YK, Singh S. Role of horizontal transmission in hepatitis B virus spread among household contacts in north India. Intervirology. 2008;51:7–13.
    1. Pande C, Sarin SK, Patra S. Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India. J Med Virol. 2011;83:962–967.
    1. Jat SL, Gupta N, Kumar T. Prevalence of hepatitis D virus infection among hepatitis B virus-infected individuals in India. Indian J Gastroenterol. 2015;34:164–168.
    1. Puri P, Anand AC, Saraswat VA. Consensus statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol. 2014;4:106–116.
    1. Chowdhury A, Santra A, Chaudhuri S. Hepatitis C virus infection in the general population: a community-based study in west Bengal, India. Hepatology. 2003;37:802–809.
    1. Singh M, Kotwal A, Gupta RM, Adhya S, Chatterjee K, Jayaram J. Sero-epidemiological and behavioural survey of HIV, HBV and HCV amongst Indian Armed Forces trainees. Med J Armed Forces India. 2010;66:50–54.
    1. Sood A, Sarin SK, Midha V. Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol. 2012;31:232–236.
    1. Dhiman RK, Satsangi S, Grover GS, Puri P. Tackling the hepatitis C disease burden in Punjab, India. J Clin Exp Hepatol. 2016;6:224–232.
    1. Solomon SS, Mehta SH, Srikrishnan AK. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis. 2015;15:36–45.
    1. Muljono DH. Epidemiology of hepatitis B and C in Republic of Indonesia. Euroasian J Hepatogastroenterol. 2017;7:55–59.
    1. Ministry of Health of the Republic of Indonesia Indonesia health profile 2016. 2016.
    1. IndexMundi Indonesia demographics profile 2018. 2018.
    1. WHO Indonesia. 2015.
    1. Purwono PB, Juniastuti, Amin M. Hepatitis B virus infection in Indonesia 15 years after adoption of a universal infant vaccination program: possible impacts of low birth dose coverage and a vaccine-escape mutant. Am J Trop Med Hyg. 2016;95:674–679.
    1. Scrutton J, Wallace J, Wait S. Situation analysis of viral hepatitis in Indonesia: a policy report. 2018.
    1. Wijayadi T, Sjahril R, Turyadi Seroepidemiology of HBV infection among health-care workers in south Sulawesi, Indonesia. BMC Infect Dis. 2018;18:279.
    1. Agency for Health Research and Development (Indonesia) Indonesia Basic Health Research 2007–2008.
    1. Agency for Health Research and Development (Indonesia) Indonesia Basic Health Research. 2013.
    1. Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in Pakistan: where do we stand? Hepat Mon. 2012;12
    1. Butt AS, Hamid S, Wadalawala AA. Hepatocellular carcinoma in native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma. BMC Res Notes. 2013;6:137–150.
    1. Bosan A, Qureshi H, Bile KM, Ahmad I, Hafiz R. A review of hepatitis viral infections in Pakistan. J Pak Med Assoc. 2010;60:1045–1058.
    1. Pervaiz A, Sipra FS, Rana TH, Qadeer I. Pre-donation screening of volunteer prisoner blood donors for hepatitis B and C in prisons of Punjab, Pakistan. J Ayub Med Coll Abbottabad. 2015;27:794–797.
    1. Butt A, Jafri W, Janjua N, Pasha O. Seroprevalence and risk factors for hepatitis C infection among male prisoners in Karachi, Pakistan. Am J Gastroenterol. 2010;105:S112.
    1. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(suppl):S15–S23.
    1. Ahmed B, Ali T, Qureshi H, Hamid S. Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. Hepatol Int. 2013;7:500–507.
    1. Tanaka J, Koyama T, Mizui M. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54:185–195.
    1. National Institute of Infectious Diseases Acute hepatitis B, April 2006–December 2015. Inf Agent Surveill Rep. 2016;37:147–148.
    1. August 2016 Infectious Agents Surveillance Report (IASR) 2016.
    1. Okuda K, Ohtsuki T, Obata h. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928.
    1. Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer. 2018;7:134–147.
    1. Ikegami N, Yoo BK, Hashimoto H. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2011;378:1106–1115.
    1. Blaxell V. Yellow blood: hepatitis C and the modernist settlement in Japan. Asia Pac J. 2014;12:1–19.
    1. Japanese Red Cross Society Haemovigilance by JRCS 2008. 2011.
    1. Shiraki K. Vertical transmission of hepatitis B virus and its prevention in Japan. In: Nishioka K, Suzuki H, Mishiro S, Oda T, editors. Viral hepatitis and liver disease. Springer; Tokyo: 1994.
    1. Afroz S, Mahtab MA, Rahman S, Khan M. Hepatitis B virus is the leading cause of cirrhosis of liver in Bangladesh. Hepatol Int. 2007;1(suppl 1):120.
    1. Mahtab MA, Rahman S, Khan M, Ahmed F, Podder PK. Aetiology of SOL of liver in Bangladesh. Indian J Gastroenterol. 2007;26(suppl 2):76.
    1. Mahtab MA, Rahman S, Karim MF. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepatobiliary Pancreat Dis Int. 2008;7:595–600.
    1. Ashraf H, Alam NH, Rothermundt C. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis. 2010;10:208–216.
    1. Islam MN, Islam KM, Islam N. Hepatitis-B virus infection in Dhaka, Bangladesh. Bangladesh Med Res Counc Bull. 1984;10:1–6.
    1. Mamun-Al-Mahtab, Akbar SM, Uddin H, Khan SI, Rahman S. Early termination of immune tolerance state of hepatitis B virus infection explains liver damage. World J Hepatol. 2014;6:621–625.
    1. Mamun-Al-Mahtab, Karim F, Foster G, Akbar SMF, Rahman S. Prevalence and risk factors of asymptomatic HCV infection in Bangladesh. J Clin Exp Hepatol. 2011;1:13–16.
    1. Khan SI, Reza MM, Crowe SM. People who inject drugs in Bangladesh–the untold burden! Int J Infect Dis. 2019;83:109–115.
    1. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16:1169–1186.
    1. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010;53:20–28.
    1. Cho EJ, Kim SE, Suk KT. Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol. 2017;23:205–211.
    1. Lee SS, Byoun YS, Jeong SH. Type and cause of liver disease in Korea: single-center experience, 2005–2010. Clin Mol Hepatol. 2012;18:309–315.
    1. Kim DY, Kim IH, Jeong SH. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int. 2013;33:586–594.
    1. Kim JY, Cho J, Hwang SH. Behavioral and healthcare-associated risk factors for chronic hepatitis C virus infection in Korea. J Korean Med Sci. 2012;27:1371–1377.
    1. Seong MH, Kil H, Kim YS. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol. 2013;85:1724–1733.
    1. National Centre for Immunisation Research and Surveillance History of immunisation in Australia.
    1. Australian Institute of Health and Welfare . Australian Institute of Health and Welfare; Canberra: 2017. Cancer in Australia 2017.
    1. Wan X, Mathews JD. Primary hepatocellular carcinoma in aboriginal Australians. Aust J Public Health. 1994;18:286–290.
    1. Waziry R, Grebely J, Amin J. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014) J Hepatol. 2016;65:1086–1093.
    1. Kalisch DW. Australian Bureau of Statistics; Canberra: 2015. National Health Survey first results Australia 2014–15 4364.0.55.001.
    1. McGregor S, McManus H, Gray R, Costello J. HIV, viral hepatitis and sexually transmitted infections in Australia: Annual surveillance report 2015. 2015.
    1. Butler JKR, Watson K, Watson A. Australian Centre for Economic Research on Health; Canberra: 2009. The impact of chronic hepatitis B in Australia: projecting mortality, morbidity and economic impact.
    1. Graham S, Guy RJ, Cowie B. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis. BMC Infect Dis. 2013;13:403–413.
    1. MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust N Z J Public Health. 2013;37:416–422.
    1. Ministerial Advisory Committee on AIDS. Sexual Health and Hepatitis. Hepatitis C Sub-Committee . Australian Government Department of Health and Ageing; Canberra: 2006. Hepatitis C Virus Projections Working Group: estimates and projections of the Hepatitis C virus epidemic in Australia.
    1. The Gastroenterological Society of Australia/Australian Liver Association The economic cost and health burden of liver diseases in Australia. 2012.
    1. Degenhardt L, Day C, Gilmour S, Hall W. The “lessons” of the Australian “heroin shortage”. Subst Abuse Treat Prev Policy. 2006;1:11–18.
    1. The Kirby Insitute . The Kirby Institute and UNSW Australia; Sydney: 2015. Main findings, bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander People: surveillance and evaluation report.
    1. Vermunt J, Fraser M, Herbison P, Wiles A, Schlup M, Schultz M. Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand. World J Gastroenterol. 2015;21:10224–10233.
    1. Petousis-Harris H, Reynolds G, Poole T, Nowlan M. 2012 antigen review for the New Zealand National Immunisation Schedule: hepatitis B. 2015.
    1. Ministry of Health . Ministry of Health; Wellington: 2012. Cancer: new registrations and deaths 2009.
    1. Ministry of Health . Ministry of Health; Wellington: 2015. Cancer: new registrations and deaths 2012.
    1. Blakely T, Bates M, Garrett N, Robson B. The incidence of hepatocellular carcinoma in New Zealand. N Z Med J. 1998;111:471–474.
    1. Chamberlain J, Sarfati D, Cunningham R, Koea J, Gurney J, Blakely T. Incidence and management of hepatocellular carcinoma among Māori and non-Māori New Zealanders. Aust N Z J Public Health. 2013;37:520–526.
    1. Epidemiology & Disease Control Division . Ministry of Health; Singapore: 2014. Singapore Burden of Disease Study 2010.
    1. Chang PE, Wong GW, Li JW, Lui HF, Chow WC, Tan CK. Epidemiology and clinical evolution of liver cirrhosis in Singapore. Ann Acad Med Singapore. 2015;44:218–225.
    1. Lee HP, Chew L, Yew CK. National Registry of Diseases Office; Singapore: 2015. Singapore Cancer Registry Interim Annual Report: trends in cancer incidence in Singapore 2010–2014.
    1. Ministry of Health Singapore The burden of disease in Singapore, 1990–2017: an overview of the Global Burden of Disease Study 2017 results. 2019.
    1. Ang SF, Ng ES, Li H. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10
    1. Ang LW, Cutter J, James L, Goh KT. Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. Vaccine. 2013;32:103–110.
    1. Lim SG. Time for action on viral hepatitis. Ann Acad Med Singapore. 2016;45:27–30.
    1. Phyo WW, Lim SG, Lee YW. Cross-sectional study on risk factors associated with hepatitis C (HCV) infection. 26th Annual Conference of APASL; Shanghai, China; Feb 15–19, 2017 (abstr PP1864).
    1. Winslow M, Subramaniam M, Ng WL, Lee A, Song G, Chan YH. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore. Singapore Med J. 2007;48:504–508.
    1. Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology54: 381–92.
    1. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310:974–976.
    1. Chen DS, Hsu NH, Sung JL. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257:2597–2603.
    1. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28:126–135.
    1. Ni YH, Chang MH, Jan CF. Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. Clin Gastroenterol Hepatol. 2016;14:1324–1330.
    1. Chen CL, Yang JY, Lin SF. Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol. 2015;63:354–363.
    1. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106:148–155.
    1. Chang MH, You SL, Chen CJ. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology. 2016;151:472–480.e1.
    1. Su WJ, Liu CC, Liu DP. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis. 2012;205:757–762.
    1. Chen HL, Chang CJ, Kong MS. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology. 2004;39:58–63.
    1. Chen DS, Kuo GC, Sung JL. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis. 1990;162:817–822.
    1. Lee MH, Yang HI, Jen CL. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991–2. Gut. 2011;60:688–694.
    1. Wang JT, Wang TH, Lin JT, Lee CZ, Sheu JC, Chen DS. Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan. J Gastroenterol Hepatol. 1995;10:454–458.
    1. Lin T, Chen CH, Chou P. Effects of combination approach on harm reduction programs: the Taiwan experience. Harm Reduct J. 2016;13:23–33.
    1. Sun P, Su N, Lin FZ. Prevalence of hepatitis A viral RNA and antibodies among Chinese blood donors. Genet Mol Res. 2015;14:16431–16437.
    1. Zhu Y, Yuan Z, Zhao Q, Chen G, Xu B. Seroprevalence of hepatitis A virus antibody in a population aged 0–30 years in Shanghai, China: implications for hepatitis A immunization. Epidemiol Infect. 2013;141:556–562.
    1. Han T, Li C, Zhang Y. The prevalence of hepatitis A virus and parvovirus B19 in source-plasma donors and whole blood donors in China. Transfus Med. 2015;25:406–410.
    1. Yu P, Huang L, Li H. Epidemiological investigation of an outbreak of hepatitis A in rural China. Int J Infect Dis. 2015;33:191–195.
    1. Jia Z, Yi Y, Liu J. Epidemiology of hepatitis E virus in China: results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006. PLoS One. 2014;9
    1. Cong W, Sui JC, Zhang XY, Qian AD, Chen J, Zhu XQ. Seroprevalence of hepatitis E virus among pregnant women and control subjects in China. J Med Virol. 2015;87:446–450.
    1. Gu G, Huang H, Zhang L, Bi Y, Hu Y, Zhou YH. Hepatitis E virus seroprevalence in pregnant women in Jiangsu, China, and postpartum evolution during six years. BMC Infect Dis. 2015;15:560–567.
    1. Aye TT, Uchida T, Ma XZ. Complete nucleotide sequence of a hepatitis E virus isolated from the Xinjiang epidemic (1986–1988) of China. Nucleic Acids Res. 1992;20
    1. Zhang L, Yan B, Xu A. A hepatitis E outbreak by genotype 4 virus in Shandong province, China. Vaccine. 2016;34:3715–3718.
    1. Zhu FC, Huang SJ, Wu T. Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China. PLoS One. 2014;9
    1. Zhang X, An J, Tu A. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Hum Vaccin Immunother. 2016;12:2322–2326.
    1. Zhang J, Zhang XF, Huang SJ. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372:914–922.
    1. Jacobson KH. World Health Organization; Geneva: 2010. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review.
    1. Jindal M, Rana SS, Gupta RK, Das K, Kar P. Serological study of hepatitis A virus infection amongst the students of a medical college in Delhi & evaluation of the need of vaccination. Indian J Med Res. 2002;115:1–4.
    1. Chadha MS, Lole KS, Bora MH, Arankalle VA. Outbreaks of hepatitis A among children in western India. Trans R Soc Trop Med Hyg. 2009;103:911–916.
    1. Goel A, Aggarwal R. Advances in hepatitis E—II: epidemiology, clinical manifestations, treatment and prevention. Expert Rev Gastroenterol Hepatol. 2016;10:1065–1074.
    1. Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med. 2007;147:28–33.
    1. Arankalle VA, Chadha MS, Chitambar SD, Walimbe AM, Chobe LP, Gandhe SS. Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982–98) J Viral Hepat. 2001;8:293–303.
    1. Mulyanto Viral hepatitis in Indonesia: past, present, and future. Euroasian J Hepatogastroenterol. 2016;6:65–69.
    1. Gunawan S, Muttaqin Z, Darti MW, et al. Prevalence of anti-HAV IgG among student in Mataram. Proceeding of Symposium Gastroenterohepatology, Mataram; Mataram, Indonesia; July 5–7, 2012 (abstr).
    1. Corwin A, Putri MP, Winarno J. Epidemic and sporadic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Am J Trop Med Hyg. 1997;57:62–65.
    1. Corwin A, Jarot K, Lubis I. Two years' investigation of epidemic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Trans R Soc Trop Med Hyg. 1995;89:262–265.
    1. Sedyaningsih-Mamahit ER, Larasati RP, Laras K. First documented outbreak of hepatitis E virus transmission in Java, Indonesia. Trans R Soc Trop Med Hyg. 2002;96:398–404.
    1. Utsumi T, Hayashi Y, Lusida MI. Prevalence of hepatitis E virus among swine and humans in two different ethnic communities in Indonesia. Arch Virol. 2011;156:689–693.
    1. Widasari DI, Yano Y, Utsumi T. Hepatitis E virus infection in two different regions of Indonesia with identification of swine HEV genotype 3. Microbiol Immunol. 2013;57:692–703.
    1. Wibawa ID, Suryadarma IG, Mulyanto Identification of genotype 4 hepatitis E virus strains from a patient with acute hepatitis E and farm pigs in Bali, Indonesia. J Med Virol. 2007;79:1138–1146.
    1. Viral Hepatitis Surveillance System—Pakistan: monthly acute viral hepatitis report, October 2014. 2014.
    1. Aziz S, Muzaffar R. Helicobacter Pylori, hepatitis viruses A, C, E, antibodies, and HBsAg-Prevention and associated factors in pediatric communities of Karachi. J Coll Physicians Surg Pak. 2007;17:195–198.
    1. Shah U, Habib Z, Kleinman RE. Liver failure attributable to hepatitis A virus infection in a developing country. Pediatrics. 2000;105:436–438.
    1. Butt AS, Sharif F. Viral Hepatitis in Pakistan: past, present, and future. Euroasian J Hepatogastroenterol. 2016;6:70–81.
    1. Butt AS, Hamid S. Hepatitis E and acute-on-chronic liver failure: outcome and predictors of mortality in Asia pacific region. 26th Annual Conference of the Asian-Pacific Association for the Study of the Liver; Shanghai, China; Feb 15–19, 2017 (abstr PP0151).
    1. Hamid SS, Atiq M, Shehzad F. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology. 2002;36:474–478.
    1. Naru T, Yousuf F, Malik A, Naz S, Ismail H. Comparison of foeto-maternal outcome in pregnant women with hepatitis E—a review of 12 years. J Pak Med Assoc. 2017;67:538–543.
    1. Iqbal T, Idrees M, Ali L. Isolation and characterization of two new hepatitis E virus genotype 1 strains from two mini-outbreaks in Lahore, Pakistan. Virol J. 2011;8:94–99.
    1. Khan A, Tanaka Y, Kurbanov F. Investigating an outbreak of acute viral hepatitis caused by hepatitis E virus variants in Karachi, South Pakistan. J Med Virol. 2011;83:622–629.
    1. Ahmad T, Waheed Y, Tahir S. Frequency of HEV contamination in sewerage waters in Pakistan. J Infect Dev Ctries. 2010;4:842–845.
    1. Khan WI, Sultana R, Rahman M. Viral hepatitis: recent experiences from serological studies in Bangladesh. Asian Pac J Allergy Immunol. 2000;18:99–103.
    1. Saha SK, Saha S, Shakur S. Community-based cross-sectional seroprevalence study of hepatitis A in Bangladesh. World J Gastroenterol. 2009;15:4932–4937.
    1. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14:38–58.
    1. Amin MZ, Siddique LN, Satter MA, Biswas KK. Increasing incidence of hepatitis A in Bangladesh. Bangladesh J Sci Ind Res. 2012;47:309–312.
    1. Harun-Or-Rashid M, Akbar SMF, Takahashi K. Epidemiological and molecular analyses of a non-seasonal outbreak of acute icteric hepatitis E in Bangladesh. J Med Virol. 2013;85:1369–1376.
    1. Labrique AB, Zaman K, Hossain Z. Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh. Am J Epidemiol. 2010;172:952–961.
    1. Mamun-Al-Mahtab, Rahman S, Khan M, Karim F. HEV infection as an aetiologic factor for acute hepatitis: experience from a tertiary hospital in Bangladesh. J Health Popul Nutr. 2009;27:14–19.
    1. Mahtab MA, Rahman S, Khan M, Karim MF. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: experience from a tertiary centre in Bangladesh. Hepatobiliary Pancreat Dis Int. 2009;8:50–52.
    1. Sohn YM, Rho HO, Park MS. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med J. 2000;41:34–39.
    1. Song MH, Lim YS, Song TJ. The etiology of acute viral hepatitis for last 3 years. Korean J Med. 2005;68:256–260.
    1. Ministry of Health and Welfare. Korea Centers for Disease Control and Prevention . Korea Centers for Disease Control and Prevention; Cheongju: 2017. Infectious diseases surveillance yearbook, 2016 (PHWR Vol 10–GL2017001)
    1. Moon S, Han JH, Bae GR, Cho E, Kim B. Hepatitis A in Korea from 2011 to 2013: current epidemiologic status and regional distribution. J Korean Med Sci. 2016;31:67–72.
    1. Jeong SH. Current status of hepatitis e virus infection in Korea. Gut Liver. 2011;5:427–431.
    1. Taniguchi M, Kim SR, Mishiro S. Epidemiology of hepatitis E in northeastern China, South Korea and Japan. J Infect. 2009;58:232–237.
    1. The Kirby Institute HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2011. 2011.
    1. Lopez L, Roos R, Cressey P, Horn B, Lee J. Ministry for Primary Industries; Wellington: 2016. Foodborne disease in New Zealand 2015.
    1. WHO . World Health Organization; Geneva: 2018. Global status report on alcohol and health 2018.
    1. Li YM, Chen WX, Yu CH. An epidemiological survey of alcoholic liver disease in Zhejiang province. Zhonghua Gan Zang Bing Za Zhi. 2003;11:647–649. (in Chinese).
    1. Lu X-I, Tao M, Luo J-Y, Gen Y, Z PR, Z H-L. Epidemiology of alcoholic liver diseases in Xi'an. Shijie Huaren Xiaohua Za Zhi. 2003;11:719–722. (in Chinese).
    1. Chen SL, Meng XD, Wang BY. An epidemiologic survey of alcoholic liver disease in some cities of Liaoning province. Zhonghua Gan Zang Bing Za Zhi. 2010;13:428–430. (in Chinese).
    1. Yao JH, Zhao QD, Xiong PF. Investigation of alcoholic liver disease in ethnic groups of Yuanjiang county in Yunnan. Weichang Bingxue He Ganbingxue Za Zhi. 2011;20:1137–1139. (in Chinese).
    1. Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28(suppl 1):11–17.
    1. Wang H, Ma L, Yin Q, Zhang X, Zhang C. Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China. Alcohol Clin Exp Res. 2014;38:1035–1041.
    1. Huang A, Chang B, Sun Y. Disease spectrum of alcoholic liver disease in Beijing 302 Hospital from 2002 to 2013: a large tertiary referral hospital experience from 7422 patients. Medicine (Baltimore) 2017;96
    1. Chang B, Li B, Sun Y. Changes in etiologies of hospitalized patients with liver cirrhosis in Beijing 302 Hospital from 2002 to 2013. Mediators Inflamm. 2017;2017
    1. Bao XY, Xu BB, Fang K, Li Y, Hu YH, Yu GP. Changing trends of hospitalisation of liver cirrhosis in Beijing, China. BMJ Open Gastroenterol. 2015;2
    1. Faridz D, Griffiths J. More than 80 dead from drinking bootleg alcohol in Indonesia. 2018.
    1. Rahman S, Ahmed MF, Alam MJ. Distribution of liver disease in Bangladesh: a cross-country study. Euroasian J Hepatogastroenterol. 2014;4:25–30.
    1. Kikuchi M, Horie Y, Ebinuma H, Taniki N, Nakamoto N, Kanai T. Alcoholic liver cirrhosis and significant risk factors for the development of alcohol-related hepatocellular carcinoma—Japan, 2012. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2015;50:222–234.
    1. Kweon S, Kim Y, Jang MJ. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES) Int J Epidemiol. 2014;43:69–77.
    1. Australian Institute of Health and Welfare . Australian Institute of Health and Welfare; Canberra: 2011. Contribution of chronic disease to the gap in mortality between Aboriginal and Torres Strait Islander people and other Australians.
    1. China Health and Family Planning Statistics Yearbook. 2017.
    1. Tang YL, Xiang XJ, Wang XY, Cubells JF, Babor TF, Hao W. Alcohol and alcohol-related harm in China: policy changes needed. Bull World Health Organ. 2013;91:270–276.
    1. GBD 2016 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1345–1422.
    1. Yu YC, Mao YM, Chen CW. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221–241.
    1. Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29:42–51.
    1. Fan JG, Zhu J, Li XJ. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43:508–514.
    1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50:204–210.
    1. Zhou YJ, Li YY, Nie YQ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13:6419–6424.
    1. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108:1299–1304.
    1. Estes C, Anstee QM, Arias-Loste MT. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.
    1. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–793.
    1. Duseja A, Singh SP, Saraswat VA. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5:51–68.
    1. Amarapurkar D, Kamani P, Patel N. Prevalence of non-alcoholic fatty liver disease: population-based study. Ann Hepatol. 2007;6:161–163.
    1. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract. 2009;84:84–91.
    1. Das K, Das K, Mukherjee PS. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593–1602.
    1. Majumdar A, Misra P, Sharma S, Kant S, Krishnan A, Pandav CS. Prevalence of nonalcoholic fatty liver disease in an adult population in a rural community of Haryana, India. Indian J Public Health. 2016;60:26–33.
    1. Siraj P, Kohli N, Srivastava VK, Natu SM. Distribution of nutrient intake among the subjects of non-alcoholic fatty liver disease in Lucknow district. Indian J Soc Res. 2012;3:37–41.
    1. Bajaj S, Nigam P, Luthra A. A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease. Indian J Med Res. 2009;129:285–292.
    1. Jali MV, Kambar S, Jali SM, Hiremath MB. Prevalence of non- alcoholic fatty liver disease among type-2diabetes mellitus patients–a cross-sectional hospital-based study. Al Ameen J Med Sci. 2015;8:50–54.
    1. Kalra S, Vithalani M, Gulati G. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT) J Assoc Physicians India. 2013;61:448–453.
    1. Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-alcoholic fatty liver disease (NAFLD) in obesity. J Clin Diagn Res. 2014;8:62–66.
    1. Kumar R, Rastogi A, Sharma MK. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab. 2013;17:665–671.
    1. Government of India Ministry of Health and Family Welfare National Family Health Survey 4 (NFHS-4) 2015–16.
    1. Chi NH, Whiting D, Forouhi N. IDF diabetes atlas, 7th edn. 2015.
    1. Duseja A, Das A, Das R. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007;52:2368–2374.
    1. Madan K, Batra Y, Gupta SD. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol. 2006;12:3400–3405.
    1. Ray G. Trends of chronic liver disease in a tertiary care referral hospital in Eastern India. Indian J Public Health. 2014;58:186–194.
    1. Asim M, Sarma MP, Kar P. Etiological and molecular profile of hepatocellular cancer from India. Int J Cancer. 2013;133:437–445.
    1. Kumar M, Kumar R, Hissar S. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22:1104–1111.
    1. Hasan I, Gani RA, Machmud R. Prevalence and risk factors for nonalcoholic fatty liver in Indonesia. J Gastroenterol Hepatol. 2002;17(suppl):S154.
    1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet. 2016;387:1513–1530.
    1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642.
    1. Younossi Z, Anstee QM, Marietti M. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
    1. Pati GK, Singh SP. Nonalcoholic fatty liver disease in south Asia. Euroasian J Hepatogastroenterol. 2016;6:154–162.
    1. Niaz A, Ali Z, Nayyar S, Fatima N. Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterol. 2011;2011
    1. Abbas Z, Saeed A, Hassan SM. Non-alcoholic fatty liver disease among visitors to a hepatitis awareness programme. Trop Gastroenterol. 2013;34:153–158.
    1. Butt AS, Hamid S, Jafri W, Salih M, Javed A. Prevalence and risk factors for NAFLD among native south Asian Pakistani patients with type II diabetes and metabolic syndrome. United Eur Gastroenterol Week. 2011 Abstract No. 11–6979.
    1. Butt AS, Hamid S, Haider Z, Salih M, Sharif F, Akhter J. NAFLD in newly diagnosed type 2 diabetes: prevalence and estimation of multiplicative effect for combination of various predicting factors. Hepatol Int. 2017;11(suppl 1):S1.
    1. Alam S, Fahim SM, Chowdhury MAB. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open. 2018;2:39–46.
    1. Rahman MM, Kibria G, Begum H. Prevalence and risk factors of nonalcoholic fatty liver disease in a rural community of south Asia. Gastroenterology. 2015;148:S145–S146.
    1. Biswas T, Garnett SP, Pervin S, Rawal LB. The prevalence of underweight, overweight and obesity in Bangladeshi adults: data from a national survey. PLoS One. 2017;12
    1. Bangladesh Demographic and Health Survey 2011 preliminary report. 2011.
    1. Biswas T, Islam A, Rawal LB, Islam SM. Increasing prevalence of diabetes in Bangladesh: a scoping review. Public Health. 2016;138:4–11.
    1. Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol. 2013;5:281–287.
    1. Tateishi R, Okanoue T, Fujiwara N. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350–360.
    1. Park SH, Jeon WK, Kim SH. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21:138–143.
    1. Lee K, Sung JA, Kim JS, Park TJ. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev. 2009;25:150–155.
    1. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–961.
    1. Lee HW, Kim BK, Kim SU. Prevalence and predictors of significant fibrosis among subjects with transient elastography-defined nonalcoholic fatty liver disease. Dig Dis Sci. 2017;62:2150–2158.
    1. Seo SH, Lee HW, Park HW. Prevalence and associated factors of nonalcoholic fatty liver disease in the health screen examinees. Korean J Med. 2006;70:26–32.
    1. Access Economics The growing cost of obesity in 2008: three years on. 2008.
    1. Burns J, Drew N, Elwel M. Overview of Aboriginal and Torres Strait Islander health status, 2018. 2019.
    1. Steering Committee for the Review of Government Service Provision . Productivity Commission; Canberra: 2016. Overcoming Indigenous disadvantage: key indicators 2016 report.
    1. Ministry of Social Development The Social Report. 2004.
    1. Ministry of Health . Ministry of Health; Wellington: 2016. Annual update of key results 2015/16: New Zealand Health Survey.
    1. Coppell KJ, Miller JC, Gray AR, Schultz M, Mann JI, Parnell WR. Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey. Obes Sci Pract. 2015;1:67–77.
    1. Khaw KB, Choi RH, Kam JH, Chakraborty B, Chow PK. Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population. Singapore Med J. 2017;58:703–707.
    1. Goh GB, Kwan C, Lim SY. Perceptions of non-alcoholic fatty liver disease–an Asian community-based study. Gastroenterol Rep. 2016;4:131–135.
    1. Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182–1188.
    1. Ministry of Health Singapore National health survey 2010. 2018.
    1. Li J, Zou B, Yeo YH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–398.
    1. Purdie E. Tracking GDP in PPP terms shows rapid rise of China and India. 2019.
    1. China Statistical Yearbook 2017. 2017.
    1. WHO China statistics summary (2002–present) 2019.
    1. WHO China key indicators. 2016.
    1. WHO Country Cooperation Strategy at a glance: China. 2018.
    1. Hou J, Wang G, Wang F. Guideline of prevention and treatment for chronic hepatitis B (2015 update) J Clin Transl Hepatol. 2017;5:297–318.
    1. Chinese Society of Hepatology. Wei L, Chinese Society of Infection Diseases. Hou JL. The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015;23:906–923. (in Chinese).
    1. Shan S, Wei W, Kong Y. China Registry of Hepatitis B (CR-HepB): protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand J Public Health. 2018 doi: 10.1177/1403494818772188. published online April 1.
    1. Greenhalgh S. Soda industry influence on obesity science and policy in China. J Public Health Policy. 2019;40:5–16.
    1. Ministry of Health and Family Welfare Government of India Situation analysis: backdrop to the National Health Policy. 2017.
    1. Berman P, Ahuja R, Bhandari L. The impoverishing effect of health care payments in India: new methodology and findings. Econ Polit Wkly. 2010;45:65–71.
    1. National Health Portal India National Viral Hepatitis Control Program (NVHCP) 2019.
    1. WHO The Global Burden of Disease 2004 update. 2008.
    1. Misra A, Sharma R, Gulati S. Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians. Diabetes Technol Ther. 2011;13:683–694.
    1. Ministry of Health and Family Welfare Government of India National multisectoral action plan for prevention and control of common noncommunicable diseases (2017–2022)
    1. Food Safety & Standards Authority of India Guidelines–code of self-regulation in food advertisement. 2009.
    1. Khandelwal S, Reddy KS. Eliciting a policy response for the rising epidemic of overweight-obesity in India. Obes Rev. 2013;14(suppl 2):114–125.
    1. Food Safety and Standards Authority of India The prevention of food adulteration act & rules (as on 1·10·2004)
    1. Maindola A. FSSAI aiming to reduce hydrogenated trans fats in Indian food to 2% 2019.
    1. The World Bank Population total Indonesia.
    1. UN Office on Drugs and Crime Harm reduction advocacy programme with members of Indonesia's Parliament concludes. 2011.
    1. Gunardi H, Zaimi LF, Soedjatmiko, Turyadi, Harahap AR, Muljono DH. Current prevalence of hepatitis B infection among parturient women in Jakarta, Indonesia. Acta Med Indones. 2014;46:3–9.
    1. Ministry of Health Republic of Indonesia Regulation of Ministry of Health of the Republic of Indonesia number 53 of 2015 concerning the control of viral hepatitis. 2015. (in Indonesian).
    1. Ministry of Health Republic of Indonesia Regulation of Ministry of Health of the Republic of Indonesia number 52 of 2017 on triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B. 2017. (in Indonesian).
    1. Law of the Republic of Indonesia number 17 of 2007 on long-term national development plan of 2005–2025.
    1. Nugraha P. Healthy lifestyle movement launched in West Nusa Tenggara. 2017.
    1. Asia Roundtable on Food Innovation for Improve Nutrition Tackling obesity in Asean: Indonesia's healthy eating campaign. 2018.
    1. O'Neill J. The “next eleven” and the world economy. 2018.
    1. World Bank Non-communicable diseases (NCDs)–Pakistan's next major health challenge. 2011.
    1. WHO-UNICEF Pakistan: WHO and UNICEF estimates of immunization coverage: 2018 revision. 2019.
    1. Waheed Y, Siddiq W. Elimination of hepatitis from Pakistan by 2030: is it possible? Hepatoma Res. 2018;4:45.
    1. WHO Regional Office for the Eastern Meditteranean Pakistan: prevention and control of hepatitis. 2019.
    1. Centers for Disease Control and Prevention (CDC) Establishment of a viral hepatitis surveillance system–Pakistan, 2009–2011. MMWR Morb Mortal Wkly Rep. 2011;60:1385–1390.
    1. WHO Pakistan: prevention and control of hepatitis. 2017.
    1. Maqbool S. Pakistan launchs its first Hepatitis Strategic Framework. 2017.
    1. Niazi AK, Niazi SK, Baber A. Nutritional programmes in Pakistan: a review. J Med Nutr Nutraceut. 2012;1:98–100.
    1. Ministry of Health Government of Pakistan, WHO Pakistan office, and Heartfile; Islamabad: 2004. National Action Plan for prevention and control of non-communicable diseases and health promotion in Pakistan.
    1. Pakistan dietary guidelines for better nutrition: my plate. 2018.
    1. Huq NM, Abul Quasem Al-Amin AQ, Ranjan Howlander SR, Kabir MA. Paying out of pocket for healthcare in Bangladesh–a burden on poor? Iran J Public Health. 2015;44:1024–1025.
    1. Paul RC, Rahman M, Wiesen E. Hepatitis B surface antigen seroprevalence among prevaccine and vaccine era children in Bangladesh. Am J Trop Med Hyg. 2018;99:764–771.
    1. Alam S, Azam G, Mustafa G, Alam M, Ahmad N. Past, present, and future of hepatitis B and fatty liver in Bangladesh. Gastroenterol Hepatol Open Access. 2017;6:00197.
    1. UN Office on Drugs and Crime The Narcotics Control Act. 1990.
    1. Bangladesh National Plan of Action for Nutrition. 1997.
    1. WHO A new Action Plan for nutrition in Bangladesh. 2019.
    1. Ministry of Local Government. Rural Development and Cooperatives National Urban Health Strategy 2014. 2014.
    1. Strategic plan for surveillance and prevention of non-communicable diseases in Bangladesh 2011–2015. 2011.
    1. World Bank Health, nutrition, and population sector program restructuring paper. 2010.
    1. Planning Wing Ministry of Health and Family Welfare. Government of the People's Republic of Bangladesh Health, population, and nutrition sector development program (2011–2016) program implementation plan volume-I. 2011.
    1. Zhang X, Oyama T. Investigating the health care delivery system in Japan and reviewing the local public hospital reform. Risk Manag Healthc Policy. 2016;9:21–32.
    1. Organisation for Economic Co-operation and Development Life expectancy at birth. 2019.
    1. Hashimoto H, Ikegami N, Shibuya K. Cost containment and quality of care in Japan: is there a trade-off? Lancet. 2011;378:1174–1182.
    1. Tatara K, Okamoto E. Japan: health system review. 2009.
    1. Oza N, Isoda H, Ono T, Kanto T. Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res. 2017;47:487–496.
    1. Ujiie M, Sasaki K, Yoshikawa N, Enami T, Shobayashi T. Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan. Lancet Inf Dis. 2016;16
    1. Uchida S, Satake M, Kurisu A. Incidence rates of hepatitis C virus infection among blood donors in Japan: a nationwide retrospective cohort study. Transfusion. 2018;58:2880–2885.
    1. Tanaka J, Mizui M, Nagakami H. Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology. 2008;51:33–41.
    1. McCurry J. Japan battles with obesity. Lancet. 2007;369:451–452.
    1. Onishi N. Japan, seeking trim waists, measures millions.
    1. Araujo C. XL problems: waistlines, gold and taxes. 2016.
    1. Organisation for Economic Co-operation and Development Country note: how does health spending in Korea compare? 2015.
    1. Kwon S, Lee T-J, Kim C-Y. World Health Organization; Geneva: 2015. Republic of Korea health system review.
    1. Chu M. How bad are ‘mukbang’ shows, really? 2018.
    1. Credit Suisse Research Institute Global wealth report 2018. 2018.
    1. Australian Taxation Office Medicare levy. 2019.
    1. Australian Institute of Health and Welfare Health expenditure Australia 2011–12: analysis by sector. 2014.
    1. Williams AH. Reduction in the hepatitis B related burden of disease–measuring the success of universal immunisation programs. Commun Dis Intell Q Rep. 2002:458–460.
    1. McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology. 2019 doi: 10.1002/hep.30899. published online Aug 16.
    1. Olsen A, Wallace J, Maher L. Responding to Australia's National Hepatitis B Strategy 2010–13: gaps in knowledge and practice in relation to Indigenous Australians. Austr J Primary Health. 2013;20:134–142.
    1. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
    1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.
    1. WHO Hepatitis B control through immunization: a reference guide. 2014.
    1. Australian Government Department of Health Third National Hepatitis B Strategy. 2018.
    1. Hajarizadeh B, Grebely J, McManus H. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol. 2017;32:229–236.
    1. The Kirby Institute Monitoring hepatitis C treatment uptake in Australia. 2017.
    1. Australian Government Department of Health Direct acting antiviral medicines for the treatment of chronic hepatitis C. 2019.
    1. Wilkinson A. Australia's progress towards hepatitis C elimination: annual report 2019. 2019.
    1. National Health and Medical Research Council Australian Government Australian guidelines to reduce health risks from drinking alcohol. 2009.
    1. Australian Bureau of Statistics Apparent consumption of alcohol, Australia, 2013–14. 2015.
    1. Australian Bureau of Statistics National Health Survey first results: Australia 2014–2015. 2015.
    1. Ridoutt B, Baird D, Bastiaans K. Changes in food intake in Australia: comparing the 1995 and 2011 National Nutrition Survey results disaggregated into basic foods. Foods. 2016;5:40–53.
    1. Brand-Miller JC, Barclay AW. Declining consumption of added sugars and sugar-sweetened beverages in Australia: a challenge for obesity prevention. Am J Clin Nutr. 2017;105:854–863.
    1. Organisation for Economic Co-operation and Development OECD economic surveys New Zealand. 2019.
    1. Ministry of Health Hepatitis C. 2019.
    1. Ministry of Health Improving the health of New Zealanders. 2019.
    1. Ministry of Health Childhood obesity plan. 2019.
    1. Ministry of Health Eating and activity guidelines for New Zealand adults. 2015.
    1. Ministry of Health Physical activity. 2017.
    1. Ministry of Health Clinical Guidelines for Weight Management in New Zealand Adults. 2018.
    1. Ministry of Health Clinical Guidelines for Weight Management in New Zealand Children and Young People. 2016.
    1. Ministry of Health Fruit in Schools programme. 2017.
    1. Ministry of Health How the Green Prescription works. 2017.
    1. Ministry of Health Active Families. 2018.
    1. Theseira L. Singapore: healthcare overview. 2015.
    1. Ministry of Health Singapore Drug subsidies & schemes. 2019.
    1. Liquor control (supply and consumption) act 2015. 2015.
    1. Lee BL. Dietary guidelinies in Singapore. Asia Pac J Clin Nutr. 2011;20:472–476.
    1. Health Promotion Board National physical activity guidelines: summary guide for professionals. 2011.
    1. Health Promotion Board The CHERISH Award. 2018.
    1. MyKenzen Healthy canteen program.
    1. The Singapore Contractors Association Circular: Health Promotion Board (HPB)–Singapore HEALTH Award 2017. 2017.
    1. Health Promotion Board Healthy Meals in Schools Programme. 2019.
    1. Lee W. Fighting fat: with TAF in Singapore. Diabetes Voice. 2003;48:49–50.
    1. Health Promotion Board Healthier Dining Programme extended to include food in hawker centres and coffee shops. 2018.
    1. Health Promotion Board Physical activity programmes. 2018.
    1. National Health Insurance Administration Ministry of Health and Welfare Conditional inclusion of oral drug treatment for hepatitis C in the national health insurance coverage as of January 24, 2017. 2017.
    1. Ministry of Justice. Ministry of Health and Welfare. Ministry of Education 2016 anti-drug report.
    1. Chiang CJ, Yang YW, Chen JD. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology. 2015;61:1154–1162.
    1. WHO Health data and health information systems in the Western Pacific.
    1. Huang JF, Wang HB, Zheng SS. Advances in China's organ transplantation achieved with the guidance of law. Chin Med J (Engl) 2015;128:143–146.
    1. Wang H, Jiang W, Zhou Z, Long J, Li W, Fan ST. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. Hepatobiliary Surg Nutr. 2013;2:188–197.
    1. Central Bureau of Health Intelligence National Health Profile 2018 13th issue. 2018.
    1. Rana SA, Sarfraz M, Kamran I, Jadoon H. Preferences of doctors for working in rural Islamabad capital territory, Pakistan: a qualitative study. J Ayub Med Coll Abbottabad. 2016;28:591–596.
    1. Nishtar S. The Gateway Paper: health systems in Pakistan, a way forward. J Pak Psychiatric Soc. 2006;3:54.
    1. Akbari AH, Rankaduwa W, Kiani AK. Demand for public health care in Pakistan. Pakistan Dev Rep. 2009;48:141–153.
    1. Kurji Z, Premani ZS, Mithani Y. Analysis of the health care system of Pakistan: lessons learnt and the way forward. J Ayub Med Coll Abbottabad. 2016;28:601–604.
    1. Hafeez Bhatti AB, Saud Dar F. Living donor liver transplantation in Pakistan. Transplantation. 2017;101:1507–1508.
    1. Constitution (Eighteenth Amendment) Act, 2010. 2010.
    1. Ahmed SM, Alam BB, Anwar I. Bangladesh health system review. 2015.
    1. Matsuda S. Health policy in Japan–current situation and future challenges. JMA J. 2019;2:1–10.
    1. Japan International Cooperation Agency Japan's experience with human resources and health policies. 2013.
    1. Organisation for Economic Co-operation and Development Health care resources. 2019.
    1. Training and certifying medical specialists. 2018.
    1. Lee SG, Moon DB, Hwang S. Liver transplantation in Korea: past, present, and future. Transplant Proc. 2015;47:705–708.
    1. World Bank Physicians (per 1000 people)–Australia. 2019.
    1. World Bank Nurses and midwives (per 1000 people)–Australia. 2019.
    1. WHO WHO global health workforce statistics database. 2018.
    1. Cumming J, McDonald J, Barr C, Martin G, Gerring Z, Daube J. World Health Organization; Manila: 2014. New Zealand health system review.
    1. Kwon JA, Dore GJ, Grebely J. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study. J Viral Hepat. 2019;26:83–92.
    1. McCaughan GW, Munn SR. Liver transplantation in Australia and New Zealand. Liver Transpl. 2016;22:830–838.
    1. Chart of the day: Singapore's number of doctors lower range for developed countries. 2018.
    1. Ministry for Communications and Information Singapore Smart Health-Assist.
    1. Ministry for Communications and Information Singapore Infocomm meda 2025.
    1. EDB Singapore How Singapore is working towards a healthier tomorrow–smartly. 2017.
    1. Muthiah M, Chong CH, Lim SG. Liver disease in Singapore. Euroasian J Hepatogastroenterol. 2018;8:66–68.
    1. Prabhakar KS. Cadaveric & living organ donation. Natural limitations. Possible solutions. Singapore experience. Ann Transplant. 2004;9:31–33.
    1. Singapore Government Human Organ Transplant (amendment) Act 2009. 2009.
    1. Ministry of Health Singapore The Medical (therapy, education and research) Act (MTERA) 2019.
    1. Cheng T-M. Taiwan's health care system: the next 20 years. 2015.
    1. Pillai VG, Chen CL. Living donor liver transplantation in Taiwan–challenges beyond surgery. Hepatobiliary Surg Nutr. 2016;5:145–150.
    1. Long Q, Xu L, Bekedam H, Tang S. Changes in health expenditures in China in 2000s: has the health system reform improved affordability. Int J Equity Health. 2013;12:40.
    1. Liang X, Guo H, Jin C, Peng X, Zhang X. The effect of new cooperative medical scheme on health outcomes and alleviating catastrophic health expenditure in China: a systematic review. PLoS One. 2012;7
    1. Yang W. China's new cooperative medical scheme and equity in access to health care: evidence from a longitudinal household survey. Int J Equity Health. 2013;12:20.
    1. Yi H, Zhang L, Singer K, Rozelle S, Atlas S. Health insurance and catastrophic illness: a report on the New Cooperative Medical System in rural China. Health Econ. 2009;18(suppl 2):S119–S127.
    1. Wang HHX, Wang JJ, Zhou ZH, Wang XW, Xu L. General practice education and training in southern China: recent development and ongoing challenges under the health care reform. Malays Fam Physician. 2013;8:2–10.
    1. Weng S, Gao S. A new account of rural drinking water safety. 2011. (in Chinese).
    1. Lim SG, Amarapurkar DN, Chan HL. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int. 2015;9:43–51.
    1. National Healthcare Security Administration National drug catalogue for basic medical insurance, work-related injury insurance and maternity insurance. 2019.
    1. Bian DD, Zhou HY, Liu S. Current treatment status and barriers for patients with chronic HCV infection in mainland China: a national multicenter cross-sectional survey in 56 hospitals. Medicine (Baltimore) 2017;96
    1. Lim SG, Aghemo A, Chen PJ. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52–62.
    1. Zu J, Li M, Zhuang G. Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model. Medicine (Baltimore) 2018;97:e0484.
    1. Major initiatives: Swachh Bharat Mission.
    1. India Today Is India really open defecation free? 2019.
    1. Kapoor D, Saxena R, Sood B, Sarin SK. Blood transfusion practices in India: results of a national survey. Indian J Gastroenterol. 2000;19:64–67.
    1. Makroo RN, Choudhury N, Jagannathan L. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. Indian J Med Res. 2008;127:140–147.
    1. Rajasekaran M, Sivagnanam G, Thirumalaikolundusubramainan P, Namasivayam K, Ravindranath C. Injection practices in southern part of India. Public Health. 2003;117:208–213.
    1. Anand K, Pandav CS, Kapoor SK. Injection use in a village in north India. Natl Med J India. 2001;14:143–144.
    1. Patel DA, Gupta PA, Kinariwala DM, Shah HS, Trivedi GR, Vegad MM. An investigation of an outbreak of viral hepatitis B in Modasa town, Gujarat, India. J Glob Infect Dis. 2012;4:55–59.
    1. Sukriti, Pati NT, Sethi A. Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India. J Gastroenterol Hepatol. 2008;23:1710–1715.
    1. Mall ML, Rai RR, Philip M. Seroepidemiology of hepatitis A infection in India: changing pattern. Indian J Gastroenterol. 2001;20:132–135.
    1. Khanna S, Vohra P, Jyoti R. Changing epidemiology of acute hepatitis in a tertiary care hospital in Northern India. Indian J Gastroenterol. 2006;25:101–102.
    1. Aggarwal R, Chen Q, Goel A. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS One. 2017;12
    1. Bhushan R, Bailay R, Sanandakumar S. In a first, Kerala imposes 14·5% ‘fat tax’ on junk food. 2016.
    1. WHO . World Health Organization; Geneva: 2015. Draft global health sector strategy on viral hepatitis, 2016–2021.
    1. Jahan M, Islam MA, Akbar SM. Anti-HBc screening of blood donors in Bangladesh: relevance to containment of HBV propagation. J Clin Exp Hepatol. 2016;6:115–118.
    1. Mahtab MA, Rahman S, Khan M, Karim F, Sharif NM, Shrestha A. Genotypes of HCV in Bangladesh: experience from a tertiary centre. Hungarian Med J. 2008;2:577–581.
    1. Uz-Zaman MH, Rahman A, Yasmin M. Epidemiology of hepatitis B virus infection in Bangladesh: prevalence among general population, risk groups and genotype distribution. Genes. 2018;9:E541.
    1. Mahmud S, Hussain M, Ahmed SS, Rahman M, Tasneem F, Afroz M. Burden of HCV in Bangladesh: warrants the screening of blood donors. Acad J Ped Neonatol. 2017;4
    1. Kim DY, Han KH, Jun B. Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea. PLoS One. 2017;12
    1. Park J, Shin A, Lee M. Prevalence of participating in physical activity from 2 Korean surveillance systems: KNHANES and KCHS. J Phys Act Health. 2018;15:763–773.
    1. Tran BT, Jeong BY, Oh J-K. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2008–2013. BMC Public Health. 2017;17:71.
    1. Yoon SK, Chun HG. Status of hepatocellular carcinoma in South Korea. Chin Clin Oncol. 2013;2:39.
    1. Sievert K, O'Neill P, Koh Y, Lee JH, Dev A, Le S. Barriers to accessing testing and treatment for chronic hepatitis B in Afghan, Rohingyan, and South Sudanese populations in Australia. J Immigr Minor Health. 2018;20:140–146.
    1. Carson PJ. Providing specialist services in Australia across barriers of distance and culture. World J Surg. 2009;33:1562–1567.
    1. Gruen RL, Bailie RS, Wang Z, Heard S, O'Rourke IC. Specialist outreach to isolated and disadvantaged communities: a population-based study. Lancet. 2006;368:130–138.
    1. Garne DL, Perkins DA, Boreland FT, Lyle DM. Frequent users of the Royal Flying Doctor Service primary clinic and aeromedical services in remote New South Wales: a quality study. Med J Aust. 2009;191:602–604.
    1. Australian Institute of Health and Welfare Medical workforce 2011. 2013.
    1. Rankin SL, Hughes-Anderson W, House AK, Heath DI, Aitken RJ, House J. Costs of accessing surgical specialists by rural and remote residents. ANZ J Surg. 2001;71:544–547.
    1. Robinson M, Slaney GM, Jones GI, Robinson JB. GP Proceduralists: ‘the hidden heart’ of rural and regional health in Australia. Rural Remote Health. 2010;10
    1. O'Sullivan BG, Joyce CM, McGrail MR. Adoption, implementation and prioritization of specialist outreach policy in Australia: a national perspective. Bull World Health Organ. 2014;92:512–519.
    1. Alavi M, Law MG, Grebely J. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study. J Hepatol. 2016;65:879–887.
    1. Patel M, Phillips-Caesar E, Boutin-Foster C. Barriers to lifestyle behavioral change in migrant South Asian populations. J Immigr Minor Health. 2012;14:774–785.
    1. Wai CT, Mak B, Chua W, Lim SG. The majority of hepatitis B carriers are not on regular surveillance in Singapore. Singapore Med J. 2004;45:423–426.
    1. Wai CT, Mak B, Chua W. Misperceptions among patients with chronic hepatitis B in Singapore. World J Gastroenterol. 2005;11:5002–5005.
    1. Wait S, Chen DS. Towards the eradication of hepatitis B in Taiwan. Kaohsiung J Med Sci. 2012;28:1–9.
    1. WHO First-ever WHO list of essential diagnostic tests to improve diagnosis and treatment outcomes. 2018.
    1. Williams R, Aspinall R, Bellis M. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet Gastroenterol Hepatol. 2014;384:1953–1997.
    1. WHO Egypt steps up efforts against hepatitis C. 2014.
    1. WHO Georgia sets sights on eliminating hepatitis C. 2015.
    1. Malaysia Ministry of Health . Malaysia Ministry of Health; Kuala Lumpur: 2014. Malaysia 2014 country response to HIV/AIDS. Reporting period: January 2013 to December 2013.
    1. WHO Alcohol initiative.
    1. WHO . World Health Organization; Geneva: 2010. Global strategy to reduce the harmful use of alcohol.
    1. UN Political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases. 2012.
    1. Hagström H, Nasr P, Ekstedt M. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2017;2:48–57.
    1. WHO Global Action Plan for the Prevention and Control of NCDs 2013–2020. 2019.
    1. World Trade Organization Declaration on the TRIPS agreement and public health. 2001.
    1. WHO Health systems financing.
    1. Heller PS. The prospects of creating ‘fiscal space’ for the health sector. Health Policy Plan. 2006;21:75–79.
    1. Taskforce on Innovative International Financing for Health Systems More money for health, and more health for the money. 2009.
    1. McCoy D, Brikci N. Taskforce on Innovative International Financing for Health Systems: what next? 2010.
Uncited Reference
    1. New Zealand Government Sale and Supply of Alcohol Act 2012. 2012.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren